Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/VRTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $490.39, up 2.38% today, with a bullish technical signal and strong institutional interest. The stock shows robust fundamentals, including a 35.51% net income margin and consistent earnings beats, supported by a recent $10 billion acquisition of Crinetics Pharmaceuticals to expand its endocrinology portfolio. Analyst consensus is strongly bullish with an 83.92% buy rating and a $538 price target, indicating potential upside.
The outlook for VRTX is positive, driven by earnings growth and strategic acquisitions, but risks include integration challenges from the Crinetics deal and competitive pressures in the pharmaceutical sector. The stock's current valuation metrics, such as a P/E of 28.68, suggest it is fairly priced relative to growth prospects, making it attractive for long-term investors despite near-term volatility.
Read full analysis

Key Stats

  • Market Cap
    $122.67B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $529.59
  • 52W Low
    $366.54
  • Typical Hold Time
    -
  • Enterprise Value
    $117.41B
  • Div Yield
    -
  • Trading Activity
    -
$477.26
52W Low: $366.54
08 Aug 2025
52W High: $529.59
06 Jul 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $529.59, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

ZenaTech's drone services enter a booming Canadian oil market with $500B+ investments and rising oil prices.

ZenaTech has expanded its drone services for the Canadian oil and gas sector by acquiring Velocity Geomatics, entering a market boosted by a 45% rise in oil prices and over $500 billion in expected investments over the next decade. This growth suppor...

Market News
1 hour ago
Na
Bullish
news icon
pluang ai news

Class action lawsuit filed against Park Ha for alleged stock manipulation and misleading investors.

A class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd. and some of its officers for allegedly misleading investors and violating federal securities laws. The complaint claims Park Ha was involved in a fraudulent stock p...

Market News
2 hours ago
Bronstein, Gewirtz & Grossman Llc
Bearish
news icon
pluang ai news

Uber to invest $1.2B in Rivian and buy 50,000 electric R2 vehicles, boosting Rivian's robotaxi prospects.

Uber has agreed to invest up to $1.2 billion in electric vehicle maker Rivian and plans to purchase up to 50,000 of Rivian's R2 electric vehicles. This deal highlights Uber's push into electric and autonomous vehicle technology, positioning Rivian as...

Market News
2 hours ago
Ryan Vanzo
Bullish
news icon
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $122.67B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $529.59
  • 52W Low
    $366.54
  • Typical Hold Time
    -
  • Enterprise Value
    $117.41B
  • Div Yield
    -
  • Trading Activity
    -
$477.26
52W Low: $366.54
08 Aug 2025
52W High: $529.59
06 Jul 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $529.59, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!